Ann: Bod expands medicinal cannabis product suite, page-7

very simple - sales revenues

what seperates companies at the moment in MC / Hemp / CBD space is talking versus delivering revenues and EXL has delivered revenues 

Their international comparison companies (charloettes web and CV Science ) have markets caps multiples well higher than their compaitive sales figures - so EXL caught up 

Here is my numbers, I focus on revenues not income as this is a land grab market at the moment so brand building, advertising spend and revenue growth are the key factors to success in my opinion

THESE NUMBERS ARE MAYBE A few weeks out of date but the picture is clear:

	ASX Code	Company	Mkt Cap	Ratio (mkt cap / revenue)	03/2019	Quarterly Revenue from 4C 12/2018	09/2018
1	AGH	ALTHEA	23.4	28.5		$82	$28
2	BDA	BOD AUSTRALIA	45.0	5.9		$766	$141
3	ZLD	ZELDA THERAPEUTICS	41.0			$0	$0
4	MXC	MGC PHARMA	49.0	6.6		$744	$135
5	CPH	CRESO PHARMA	55.0	25.1		$219	$170
6	MDC	MEDLAB CLINICAL	87.0	6.9		$1,269	$1,222
7	AC8	AUSCANN	188.0			$0	$0
8	CAN	CANN GROUP	297.0			$1	$2
9	EXL	ELIXINOL	445.0	3.9		$11,334	$9,831
10						$14,415	$11,529